Search: onr:"swepub:oai:DiVA.org:uu-482041" >
Reduction of alpha ...
Reduction of alpha SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody
-
- Roshanbin, Sahar, 1984- (author)
- Uppsala universitet,Geriatrik
-
- Julku, Ulrika (author)
- Uppsala universitet,Geriatrik
-
- Xiong, Mengfei (author)
- Uppsala universitet,Geriatrik
-
show more...
-
- Eriksson, Jonas (author)
- Uppsala universitet,Preparativ läkemedelskemi,Uppsala Univ Hosp, PET Ctr, S-75185 Uppsala, Sweden.
-
- Masliah, Eliezer (author)
- NIA, Div Neurosci & Lab Neurogenet, NIH, Bethesda, MD 20814 USA.
-
- Hultqvist, Greta, 1980- (author)
- Uppsala universitet,Institutionen för farmaci
-
- Bergström, Joakim (author)
- Uppsala universitet,Geriatrik
-
- Ingelsson, Martin (author)
- Uppsala universitet,Geriatrik,Univ Hlth Network, Krembil Brain Inst, Toronto, ON M5T 1M8, Canada.;Univ Toronto, Dept Med, Toronto, ON M5T 1M8, Canada.;Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5T 1M8, Canada.
-
- Syvänen, Stina (author)
- Uppsala universitet,Geriatrik
-
- Sehlin, Dag, 1976- (author)
- Uppsala universitet,Geriatrik
-
show less...
-
(creator_code:org_t)
- 2022-07-05
- 2022
- English.
-
In: Pharmaceutics. - : MDPI AG. - 1999-4923. ; 14:7
- Related links:
-
https://doi.org/10.3...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- Immunotherapy targeting aggregated alpha-synuclein (alpha SYN) is a promising approach for the treatment of Parkinson's disease. However, brain penetration of antibodies is hampered by their large size. Here, RmAbSynO2-scFv8D3, a modified bispecific antibody that targets aggregated alpha SYN and binds to the transferrin receptor for facilitated brain uptake, was investigated to treat alpha SYN pathology in transgenic mice. Ex vivo analyses of the blood and brain distribution of RmAbSynO2-scFv8D3 and the unmodified variant RmAbSynO2, as well as in vivo analyses with microdialysis and PET, confirmed fast and efficient brain uptake of the bispecific format. In addition, intravenous administration was shown to be superior to intraperitoneal injections in terms of brain uptake and distribution. Next, aged female alpha SYN transgenic mice (L61) were administered either RmAbSynO2-scFv8D3, RmAbSynO2, or PBS intravenously three times over five days. Levels of TBS-T soluble aggregated alpha SYN in the brain following treatment with RmAbSynO2-scFv8D3 were decreased in the cortex and midbrain compared to RmAbSynO2 or PBS controls. Taken together, our results indicate that facilitated brain uptake of alpha SYN antibodies can improve treatment of alpha SYN pathology.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- bispecific antibody
- blood-brain barrier (BBB)
- alpha-synuclein (alpha SYN)
- Parkinson's disease (PD)
- immunotherapy
- monoclonal antibody
- transferrin receptor (TfR)
- receptor-mediated transcytosis (RMT)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Roshanbin, Sahar ...
-
Julku, Ulrika
-
Xiong, Mengfei
-
Eriksson, Jonas
-
Masliah, Eliezer
-
Hultqvist, Greta ...
-
show more...
-
Bergström, Joaki ...
-
Ingelsson, Marti ...
-
Syvänen, Stina
-
Sehlin, Dag, 197 ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Pharmaceutics
- By the university
-
Uppsala University